ArticleTheranostics2020
Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Radiation-Responsive Promoters: Molecular Mechanisms, Screening Strategies, and Translational Applications as Radiation Biomarkers.Current issues in molecular biology · 2026Review
- TGF-β1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Imaging of adeno-associated viral capsids for purposes of gene editing using CEST NMR/MRI.Magnetic resonance in medicine · 2024Article
- Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice.Molecular therapy oncolytics · 2023Article
- Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma.Molecular therapy oncolytics · 2022Article
- The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy.EJNMMI research · 2022Review
- Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Selective sodium iodide symporter (Molecular therapy oncolytics · 2021Article
- Glucose Transporters as a Target for Anticancer Therapy.Cancers · 2021Review
- Pseudogene HSPA7 is a poor prognostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) and correlated with immune infiltrates.Cancer cell international · 2021Article
- Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Improved Noninvasive In Vivo Tracking of AAV-9 Gene Therapy Using the Perchlorate-Resistant Sodium Iodide Symporter from Minke Whale.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- NoninvasiveWorld journal of stem cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.